313346-39-3

Basic information

• Product Name: 3-(CyclohexylsulfaMoyl)benzoic acid
• Synonyms: 3-(CyclohexylsulfaMoyl)benzoic acid
• CAS NO: 313346-39-3
• Molecular Formula: C₁₃H₁₇NO₄S
• Molecular Weight: 283.34338
• Mol File: 313346-39-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(CyclohexylsulfaMoyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(CyclohexylsulfaMoyl)benzoic acid(313346-39-3)
• EPA Substance Registry System: 3-(CyclohexylsulfaMoyl)benzoic acid(313346-39-3)

Safety Data

• Hazardous Substances Data: 313346-39-3(Hazardous Substances Data)

Upstream product

• 4025-64-3 3-Carboxybenzenesulfonyl chloride 
• 108-91-8 cyclohexylamine 

Downstream Products

• 503068-86-8 N-cyclohexyl-3-(hydroxymethyl)benzenesulfonamide 
• 1572509-62-6 3-(cyclohexylsulfamoyl)-N-(4-fluorophenyl)benzamide 

Relevant articles and documents

Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)

Small molecule induced hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV. Here we describe efforts toward the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compound used to further profile the mode of action. Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log reduction of the HBV DNA viral load.

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.

PHENETHANOLAMINE DERIVATIVES

The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.